+44 (0) 1829 824 825 info@aspectscientific.com

Alzheimer's Research DRG Amyloid beta ELISAs

The first test worldwide for the determination of serum auto-antibodies against Amyloid peptides

DRG Diagnostics logo

DRG Amyloid beta ELISA kits are solid phase enzyme-linked immunosorbent assays (ELISA) based on the sandwich principle.

Benefits of DRG Amyloid beta ELISAs

  • Amyloid auto-antibodies are supposed to regulate the concentration of Amyloid beta (Aβ) peptides in the body, which might be helpful to protect against Alzheimer´s disease.
    The DRG ELISA is the first test worldwide for the determination of serum auto-antibodies against Amyloid peptides. Already today IVIG (Intravenous Immunoglobulin) – the purified IgG fraction of human plasma – is used as therapeutics in the field of several neurological disorders.
  • Serum, plasma or CSF contains Amyloid beta peptides of different size. Amyloid beta (1-40) containing 40 amino acids are the most abundant Aβ peptides, while the concentration of Aβ 1-42 is approximately 10 times lower.
    Due to its outstanding sensitivity, the DRG Elisa Abeta (1-40) specifically detects
    1-40 peptides not only in CFS, but also in serum and plasma samples.
  • The lyophilized standards just have to be resolved in distilled water. All other reagents are ready-to-use.
  • The combination of both ELISAs can offer insight into the correlation and mutual influence of Aβ (1-40) peptides and their corresponding auto-antibodies.
DRG Preeclampsia - PLGF ELISA
Alzheimer's Research DRG Amyloid Beta ELISA.ai

Contact us today to find out more and speak to one of our experts about Alzheimer’s Research DRG Amyloid beta ELISAs